CD­MO se­cures a $98M+ NIH con­tract for pro­duc­tion of pe­di­atric HIV-pre­ven­tion prod­ucts

Ad­vanced Bio­Science Lab­o­ra­to­ries, a CD­MO spe­cial­iz­ing in bio­ther­a­pies, vi­ral vec­tor-based vac­cines and on­colyt­ics, has re­ceived a de­vel­op­ment and man­u­fac­tur­ing con­tract from the US gov­ern­ment.

ABL has been award­ed a sev­en-year con­tract with a po­ten­tial val­ue of $98.9 mil­lion to pro­vide re­sources to Pe­di­atrics and HIV Pre­ven­tion Sci­ence by the Na­tion­al In­sti­tutes of Health’s Di­vi­sion of AIDS. Specif­i­cal­ly, ABL will pro­vide the Di­vi­sion of AIDS with pre­clin­i­cal work, an­i­mal mod­els and an­a­lyt­i­cal ser­vices man­u­fac­tur­ing to ad­vance non-vac­cine bio­med­ical HIV prod­ucts such as in­trav­agi­nal rings and long-act­ing in­jecta­bles that aim to pre­vent STIs, HIV or preg­nan­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER